ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) will acquire Spark Therapeutics Inc. (NASDAQ:ONCE) for $4.8 billion in a deal that marks the Swiss pharma's first major move into gene therapy.
The deal announced early Monday was the first major acquisition since James Sabry became global head of pharma partnering (see “Roche’s Partnering Priority”). ...